Literature DB >> 24998779

PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.

Jung-Young Park1, Fan Zhang1, Paul R Andreassen2.   

Abstract

PALB2 was first identified as a partner of BRCA2 that mediates its recruitment to sites of DNA damage. PALB2 was subsequently found as a tumor suppressor gene. Inherited heterozygosity for this gene is associated with an increased risk of cancer of the breast and other sites. Additionally, biallelic mutation of PALB2 is linked to Fanconi anemia, which also has an increased risk of developing malignant disease. Recent work has identified numerous interactions of PALB2, suggesting that it functions in a network of proteins encoded by tumor suppressors. Notably, many of these tumor suppressors are related to the cellular response to DNA damage. The recruitment of PALB2 to DNA double-strand breaks at the head of this network is via a ubiquitin-dependent signaling pathway that involves the RAP80, Abraxas and BRCA1 tumor suppressors. Next, PALB2 interacts with BRCA2, which is a tumor suppressor, and with the RAD51 recombinase. These interactions promote DNA repair by homologous recombination (HR). More recently, PALB2 has been found to bind the RAD51 paralog, RAD51C, as well as the translesion polymerase pol η, both of which are tumor suppressors with functions in HR. Further, an interaction with MRG15, which is related to chromatin regulation, may facilitate DNA repair in damaged chromatin. Finally, PALB2 interacts with KEAP1, a regulator of the response to oxidative stress. The PALB2 network appears to mediate the maintenance of genome stability, may explain the association of many of the corresponding genes with similar spectra of tumors, and could present novel therapeutic opportunities.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; DNA repair; Genome stability; Homologous recombination; PALB2; Tumor suppressor

Mesh:

Substances:

Year:  2014        PMID: 24998779      PMCID: PMC4183126          DOI: 10.1016/j.bbcan.2014.06.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  160 in total

1.  Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.

Authors:  Christian Bowman-Colin; Bing Xia; Samuel Bunting; Christiaan Klijn; Rinske Drost; Peter Bouwman; Laura Fineman; Xixi Chen; Aedin C Culhane; Hong Cai; Scott J Rodig; Roderick T Bronson; Jos Jonkers; Andre Nussenzweig; Chryssa Kanellopoulou; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-08       Impact factor: 11.205

Review 2.  The chromatin response to DNA breaks: leaving a mark on genome integrity.

Authors:  Godelieve Smeenk; Haico van Attikum
Journal:  Annu Rev Biochem       Date:  2013-02-14       Impact factor: 23.643

3.  Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia.

Authors:  Massimo Bogliolo; Beatrice Schuster; Chantal Stoepker; Burak Derkunt; Yan Su; Anja Raams; Juan P Trujillo; Jordi Minguillón; María J Ramírez; Roser Pujol; José A Casado; Rocío Baños; Paula Rio; Kerstin Knies; Sheila Zúñiga; Javier Benítez; Juan A Bueren; Nicolaas G J Jaspers; Orlando D Schärer; Johan P de Winter; Detlev Schindler; Jordi Surrallés
Journal:  Am J Hum Genet       Date:  2013-04-25       Impact factor: 11.025

4.  MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination.

Authors:  Fan Zhang; Gregory Bick; Jung-Young Park; Paul R Andreassen
Journal:  J Cell Sci       Date:  2012-10-04       Impact factor: 5.285

5.  Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Authors:  Bridgid E Hast; Dennis Goldfarb; Kathleen M Mulvaney; Michael A Hast; Priscila F Siesser; Feng Yan; D Neil Hayes; Michael B Major
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

Review 6.  Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.

Authors:  C Zagni; U Chiacchio; A Rescifina
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 7.  Structural mechanisms underlying signaling in the cellular response to DNA double strand breaks.

Authors:  Inbal Mermershtain; J N Mark Glover
Journal:  Mutat Res       Date:  2013-07-27       Impact factor: 2.433

8.  RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.

Authors:  Ahrum Min; Seock-Ah Im; Young-Kwang Yoon; Sang-Hyun Song; Hyun-Jin Nam; Hyung-Seok Hur; Hwang-Phill Kim; Kyung-Hun Lee; Sae-Won Han; Do-Youn Oh; Tae-You Kim; Mark J O'Connor; Woo-Ho Kim; Yung-Jue Bang
Journal:  Mol Cancer Ther       Date:  2013-03-19       Impact factor: 6.261

9.  Heterozygous mutations in PALB2 cause DNA replication and damage response defects.

Authors:  Jenni Nikkilä; Ann Christin Parplys; Katri Pylkäs; Muthiah Bose; Yanying Huo; Kerstin Borgmann; Katrin Rapakko; Pentti Nieminen; Bing Xia; Helmut Pospiech; Robert Winqvist
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  36 in total

1.  Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells.

Authors:  Sarah R Hengel; Eva Malacaria; Laura Folly da Silva Constantino; Fletcher E Bain; Andrea Diaz; Brandon G Koch; Liping Yu; Meng Wu; Pietro Pichierri; M Ashley Spies; Maria Spies
Journal:  Elife       Date:  2016-07-19       Impact factor: 8.140

2.  A systematic review of predicted pathogenic PALB2 variants: an analysis of mutational overlap between epithelial cancers.

Authors:  Boris Janssen; Sarah Bellis; Thomas Koller; Marc Tischkowitz; Siong-Seng Liau
Journal:  J Hum Genet       Date:  2019-10-16       Impact factor: 3.172

Review 3.  The control of DNA repair by the cell cycle.

Authors:  Nicole Hustedt; Daniel Durocher
Journal:  Nat Cell Biol       Date:  2016-12-23       Impact factor: 28.824

4.  Coordination of the recruitment of the FANCD2 and PALB2 Fanconi anemia proteins by an ubiquitin signaling network.

Authors:  Gregory Bick; Fan Zhang; A Ruhikanta Meetei; Paul R Andreassen
Journal:  Chromosoma       Date:  2016-06-08       Impact factor: 4.316

5.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

6.  RECQL: a new breast cancer susceptibility gene.

Authors:  Taraswi Banerjee; Robert M Brosh
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 7.  Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia.

Authors:  Nicholas E Mamrak; Akiko Shimamura; Niall G Howlett
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

Review 8.  Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.

Authors:  Sarah R Hengel; M Ashley Spies; Maria Spies
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

9.  Discovery of mutations in homologous recombination genes in African-American women with breast cancer.

Authors:  Yuan Chun Ding; Aaron W Adamson; Linda Steele; Adam M Bailis; Esther M John; Gail Tomlinson; Susan L Neuhausen
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

10.  Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.

Authors:  Helmut Hanenberg; Paul R Andreassen; Jung-Young Park; Elizabeth L Virts; Anna Jankowska; Constanze Wiek; Mohamed Othman; Sujata C Chakraborty; Gail H Vance; Fowzan S Alkuraya
Journal:  J Med Genet       Date:  2016-05-20       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.